Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]MNI-958 PET Imaging in AD, PSP, and Healthy Volunteers
NCT03545789Phase 1Completed
- Sponsor
- Invicro
- Start
- Mar 2018
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of florzolotau, sponsored by Invicro. Primary endpoint: Regional [18F]MNI-958 binding/uptake at 1 year. Started Mar 2018; status: completed.
02
Drugs
florzolotau
Beyond the preview
Go deeper on NCT03545789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03545789.